Page 8

Foreword

Juan Carlos Kaski is Professor of Cardiovascular Science at St George’s, University of London (SGUL), UK, Honorary Consultant Cardiologist at St George’s Hospital NHS Trust, London, and immediate past director of the Cardiovascular and Cell Sciences Research Institute at SGUL. Professor Kaski is a Doctor of Science, University of London, an immediate past president of the International Society of Cardiovascular Pharmacotherapy (ISCP), and an editorial board member and associate editor of numerous peer-review journals. He is also fellow of the European Society of Cardiology (ESC), American College of Cardiology (ACC), American Heart Association (AHA), Royal College of Physicians (RCP) and over 30 other scientific societies worldwide. Professor Kaski’s research areas include mechanisms of rapid coronary artery disease progression, inflammatory and immunological mechanisms of atherosclerosis, microvascular angina and biomarkers of cardiovascular risk. Professor Kaski has published more than 450 papers in peer-reviewed journals, more than 200 invited papers in cardiology journals and more than 130 book chapters. He has also edited six books on cardiovascular topics.

T

his is a particularly exciting time for European Cardiology Review. It gives me great pleasure to announce that the journal is now indexed in PubMed. This outstanding achievement is the result of the extremely hard work of everyone involved in the journal in different capacities, in particular the publisher, Radcliffe Cardiology.

The current issue includes insightful contributions on heart failure (Lupón and Bayes-Genis), cardio-rheumatology (Mavrogeni et al.) and obesity (Conti) by international leaders in their fields. Also, Ibrahim et al discuss the mechanisms and management of erectile dysfunction, an important condition linked to ischaemic heart disease (IHD) that affects an increasingly large proportion of individuals worldwide. The Pharmacotherapy section of the journal is of utmost interest, featuring the pharmacogenomics of antiplatelet agents (Tan Su-Yin), whilst Guarini et al. address many novel therapeutic issues related to the use of metabolic modulators, and Facila Rubio et al. examine non-vitamin K antagonists for prevention of cardiovascular events in high-risk patients with documented IHD and those with peripheral artery disease. Hasegawa edits a section that presents the best abstracts from the ISCP Annual Scientific Meeting 2018, which took place in Kyoto in May. Last but not least, the Cardiology Masters section in this issue portrays the professional life of one of the most outstanding female scientists of our time, cardiac pathologist Dr Renu Virmani. I have truly enjoyed editing this issue and hope you too will enjoy its content. With the end-of-year festivities upon us, I would like to wish you all a peaceful and prosperous New Year. n

DOI: https://doi.org/10.15420/ecr.2018.13.2.FO

90

Access at: www.ICRjournal.com

ECR_Kaski_Foreword_FINAL.indd 90

© RADCLIFFE CARDIOLOGY 2018

16/12/2018 13:34

ECR 13.2  

European Cardiology Review Volume 13 Issue 2 Winter 2018

ECR 13.2  

European Cardiology Review Volume 13 Issue 2 Winter 2018